News | March 09, 2021
NATCO receives approval for Everolimus tablets for the US market
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
NATCO's partner BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks.
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
ranules now has a total of 38 ANDA approvals from US FDA.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
posaconazole delayed-release tablets 100 mg are the generic equivalent of Noxafil.
The centralized marketing authorization granted by the EC is valid in all EU Member
Tavaborole Topical Solution, 5%, is an oxaborole antifungal.
Subscribe To Our Newsletter & Stay Updated
